# ATAC - Arimidex, Tamoxifen Alone or in Combination

> **NCT00849030** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 9358 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Anastozole (Arimidex)
- **DRUG:** Tamoxifen (Nolvadex)
- **DRUG:** Anastozole (Arimidex) placebo
- **DRUG:** Tamoxifen (Nolvadex) placebo

## Key facts

- **NCT ID:** NCT00849030
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-07
- **Primary completion:** 2001-06
- **Final completion:** 2010-04
- **Target enrollment:** 9358 (ACTUAL)
- **Last updated:** 2012-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00849030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00849030, "ATAC - Arimidex, Tamoxifen Alone or in Combination". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00849030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*